Robert Wasserman
Stock Analyst at Benchmark
(3.36)
# 916
Out of 5,182 analysts
119
Total ratings
48.62%
Success rate
2.22%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $86.85 | +9.38% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $64.49 | +39.56% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $199.59 | +10.23% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $57.77 | -4.79% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $5.70 | +557.89% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $53.13 | +41.16% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $8.47 | +77.10% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.54 | +289.61% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $32.98 | +6.12% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.52 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $19.51 | +53.77% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $2.87 | +74.22% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $8.23 | +45.81% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.82 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $117.78 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.56 | +12.51% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.77 | +3,510.11% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.60 | +2,784.62% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $191.12 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $491.46 | +18.02% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $86.85
Upside: +9.38%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $64.49
Upside: +39.56%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $199.59
Upside: +10.23%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $57.77
Upside: -4.79%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $5.70
Upside: +557.89%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $53.13
Upside: +41.16%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $8.47
Upside: +77.10%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.54
Upside: +289.61%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $32.98
Upside: +6.12%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.52
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $19.51
Upside: +53.77%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $2.87
Upside: +74.22%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.23
Upside: +45.81%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.82
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $117.78
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.56
Upside: +12.51%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.77
Upside: +3,510.11%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.60
Upside: +2,784.62%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $191.12
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $491.46
Upside: +18.02%